Made available in DSpace on 2014-06-11T19:23:43Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-02-11Bitstream added on 2014-06-13T20:11:27Z : No. of bitstreams: 1 cesar_jrf_me_jabo.pdf: 550352 bytes, checksum: 1d6db13e1ea88e0f7e6d7733821abce1 (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Tendo em vista a relação da cicloxigenase-2 com a progressão do câncer, objetivou-se neste trabalho avaliar a expressão da atividade desta enzima com a imunorreatividade de macrófagos no diagnóstico e prognóstico de mastocitoma canino. Para a realização deste estudo foram selecionadas 24 amostras de mastocitomas e 5 amostras de tecido cutâneo sem alterações patológicas (grupo controle). Os espécimes foram divididos em grupos: GO ¬ grupo controle (n=5), G1 -mastocitomas grau I (n=8) , G2 - mastocitomas grau 11 (n=8), G3 - mastocitomas grau 11I (n=8). A avaliação da expressão da COX-2 e macrófagos foi conduzida por imunoistoquímica, utilizando-se o complexo avidina-biotina (ABC). Os resultados mostraram que os dois anticorpos imunorreagiram com tecidos caninos normais ou neoplásicos. A expressão da COX-2 mostrou marcação crescente, conforme a agressividade do tumor e houve significância (P<O,05) entre os grupos GO e G1; GO e G2; GO e G3; G1 e G3. A imunomarcação de macrófagos foi decrescente em relação à gradação histológica e-houve significância (P<O,05) entre os grupos GO e G1; GO e G2; GO e G3; G1 e G3; G2 e G3. Assim como a expressão de macrófagos, a sobrevida dos animais foi decrescente em relação ao grau de malignidade do tumor e inversamente proporcional a marcação de COX-2. / Considering the relationship between cyclooxygenase-2 (COX-2) with the cancer evolution, this study aimed to assessment the expression of this enzyme with the immunoreactive of macrophage in the diagnosis and prognostic of canine mast cell tumor. Twenty four mast cell tumors samples were selected for the accomplishment of this study and tive samples of normal skin tissue (control group - GO). The samples were divided in groups: GO ¬ control group (n=5), G1 - mastocytoma grade I (n=8), G2 - mastocytoma grade 11 (n=8), G3 - mastocytoma grade 11I (n=8). The evaluation of the COX-2 and macrophage expression was achieved by immunohistochemistry, by means of complex avidine-biotine (ABC). The COX-2 expression increased, as the tumor grade progression; moreover. it had relevancy (P<O,05) among the groups: GO and G1, GO and G2, GO and G3, G1 and G3. The macrophage immunoreactive was decreased in relation of histological grade and it had a relevancy (P<O,05) among the groups: GO and G1, GO and G2. GO and G3. G1 and G3, G2 and G3. As macrophage expression, animal survival was decreased in relation of the histological grade of tumor and proportional reversed COX-2 expression.

Orientadores: Konradin Metze, Randall Luis Adam / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-16T05:29:25Z (GMT). No. of bitstreams: 1 Elston_LilianBarreto_D.pdf: 2689434 bytes, checksum: 2eeb1a5a1e47810949c3286be8cd9633 (MD5) Previous issue date: 2009 / Resumo: O sistema de graduação histológica desenvolvido por Patnaik et al. (1984), provou ser de relevância prognóstica nos Mastocitomas Cutâneos Caninos (MCC). Os parâmetros subjetivos utilizados em sua graduação têm levado patologistas veterinários a conferir diferentes graus a uma mesma amostra. Este fato pode refletir negativamente no estabelecimento do protocolo terapêutico baseado em tal método. A ampliação das possibilidades de ferramentas prognósticas objetivas pode auxiliar a diminuir o problema da concordância da graduação. Este estudo tem por objetivo calcular a concordância entre observadores no processo de graduação, estabelecer quais os parâmetros são de relevância prognóstica, desenvolver nova técnica simplificada de graduação baseada em parâmetros histológicos de concordância adequada, e estabelecer a relevância prognóstica das variáveis de sociologia celular como ferramenta prognóstica objetiva e confiável. Grau de Patnaik, parâmetros histológicos e o coeficiente kappa livre de margens foram calculados para cada uma das amostras dos 81 cães de diferentes raças, sexo, e idade. De 56 destas amostras foram obtidos dados quanto à sobrevida e, de suas lâminas histológicas, foram adquiridas imagens digitalizadas para fins de análise sintática estrutural (ASE). ASE das amostras, mediante construção de grafos como Mosaico Voronoi (MV), Triangulação Delaunay (TD) e Árvore Geradora Mínima (AGM), foi automaticamente realizada pelo programa "Sociology" desenvolvido pelo Dr. Randall Luiz Adam. Nossos resultados confirmaram a fraca concordância do método de Patnaik para graduação dos MCCs por três experimentados patologistas veterinários (Kfree=0,28). A avaliação mitótica (quanto maior o seu número pior o prognóstico) e a granulação intracitoplasmática (quanto mais granulação melhor o prognóstico) revelaram-se como variáveis independentes de relevância prognóstica (B=0.760 e -0,989; p=0,045 e 0,014 respectivamente) e com razoável concordância (Kfree?0,35), quando todas as variáveis relevantes (p?0,05) quanto à sobrevida e de razoável concordância foram submetidas à análise multivariada pela Regressão de Cox. Deste modo, desenvolveu-se um método simples, sob a forma de escore o qual variava de -2 a +2 (porquanto a granulação tem caráter protetor sendo B = - 0,989) e se mostrava estatisticamente significativo para sobrevida (p?0,004). Por outro lado, o estudo da sociologia celular revelou que, os coeficientes de variação (CV) do perímetro, da esfericidade e da área dos polígonos do MV (p=0.029, p=0,028 e p= 0,031 respectivamente), o CV dos ângulos máximos dos triângulos da TD (p=0,026), provaram ser variáveis objetivas significativas, indicando a relação entre desordem arquitetural e malignidade. Desta forma o estudo matemático da arquitetura tissular de MCCs revelou-se como uma nova e promissora ferramenta na avaliação prognóstica de MCCs. / Abstract: Histological based grading system developed by Patnaik et al. (1984) has proved to be of prognostic relevance in Cutaneous Mast cell tumors (CMC). The subjective histological parameters used in grading may lead different veterinary pathologists to access different grade for the same MCC, this fact may negatively reflect in the treatment protocol based on this grading system. Disclosing new objective prognostic tools may help to minimize the problem of grading. The aim of this study is to calculate interobserver agreement in the grading process, to establish which histological parameters are of prognostic relevance, to reveal a novel simplified prognostic technique based on these parameters and to establish the prognostic relevance of cellular sociology parameters as an objective prognostic tool. Patnaik's grade, histological parameters and the Kappa free coefficient were calculate for each one of eighty-one dogs from different breeds, sex, and ages. From 56 with defined survival time we achieved digitalized images with cellular sociology purposes. The "Sociology" software then performed syntactic Structural Analysis (SSA) with Voronoi Tessellation (VT), Delaunay Triangulation (DT) and Minimum Spanning Tree (MST). Our results statistically confirmed the poor interobserver agreement in the MCC grading (Kfree= 0,28). When all agreement and prognostic relevant parameters were submitted to multivariate analyses with Cox regression, mitotic evaluation and intracitoplasmatic granulation showed to be independents parameters with prognostic relevance (B= 0,760 e -0,989; p= 0,045 and p=0,014) and with reasonable agreement (Kfree<0,35). We performed a score that varies from -2 to +2 (since granulation is a protective one) with these two relevant parameters. This new simple score system significantly correlated to survival (p ? 0,004). In the other hand, the prognostic relevance of cellular sociology, reveals that coefficient of variation (CV) of perimeter, area and roundness from Voronoi polygons (p=0,029; 0,031; 0,028 respectively) and CV of maximum angle of DTs (p=0,026) are significant objective parameters. These findings indicated the relationship between structural disorder and malignancy of MCTs and pointed out SSA as a new reliable tool to prognosticate MCTs. / Doutorado / Biologia Estrutural, Celular, Molecular e do Desenvolvimento / Doutor em Fisiopatologia Medica

A desregulação da apoptose, principalmente da via mitocondrial, exerce papel na progressão tumoral, resistência à quimioterapia, além de favorecer a formação de metástases por permitir a sobrevivência de células tumorais na circulação e outros microambientes teciduais. No presente estudo, foram avaliados 58 mastocitomas cutâneos caninos, provenientes de 50 animais submetidos à cirurgia excisional como única forma de tratamento. Os tumores foram graduados de acordo com o sistemas de estabelecidos por Patnaik, Ehler e MacEwen (1984) e Kiupel et al. (2011). As expressões das proteínas relacionadas à via intrínseca da apoptose, BCL2, BAX, APAF1, Caspase 9 e Caspase 3, foram caracterizadas por meio de imuno-histoquímica. Os resultados obtidos das imunomarcações foram comparados às graduações histopatológicas, bem como à mortalidade em função do tumor e ao tempo de sobrevida pós-cirúrgico. Observamos maior expressão de BAX em mastocitomas de grau III, bem como menor expressão de BCL2 em tumores de alto grau. A detecção imuno-histoquímica de BAX foi considerada um indicador prognóstico para sobrevida e mortalidade em função da doença, enquanto que as de APAF1 e BCL2 adicionaram valor prognóstico às graduações histopatológicas melhorando a previsão da sobrevida pós-cirurgia / Deregulation of apoptosis, especially in the mitochondrial pathway, plays a role in tumor progression, resistance to chemotherapy, and favor the formation of metastases by allowing the survival of tumor cells in the blood stream and other tissue microenvironments. In the present study, we evaluated 58 canine cutaneous mast cell tumors, from 50 dogs, which were submitted to excisional surgery alone. The tumors were graded according to the systems proposed by Patnaik, Ehler and MacEwen (1984) and Kiupel et al. (2011). The expression of the apoptosis-related proteins BCL2, BAX, APAF1, caspase 9 and caspase 3 was characterized by immunohistochemistry. Immunohistochemical results were compared with the histopathological grades, mortality due to the tumor and post-surgical survival time. We observed increased expression of BAX in grade III mast cell tumors and lower expression of BCL2 in high-grade tumors. Immunohistochemical detection of BAX was considered an independent indicator of prognosis for survival and mortality due to the disease, whereas APAF1 and BCL2 added prognostic value to the histopathological grading systems improving the prediction of survival post surgery

A desregulação da apoptose, principalmente da via mitocondrial, exerce papel na progressão tumoral, resistência à quimioterapia, além de favorecer a formação de metástases por permitir a sobrevivência de células tumorais na circulação e outros microambientes teciduais. No presente estudo, foram avaliados 58 mastocitomas cutâneos caninos, provenientes de 50 animais submetidos à cirurgia excisional como única forma de tratamento. Os tumores foram graduados de acordo com o sistemas de estabelecidos por Patnaik, Ehler e MacEwen (1984) e Kiupel et al. (2011). As expressões das proteínas relacionadas à via intrínseca da apoptose, BCL2, BAX, APAF1, Caspase 9 e Caspase 3, foram caracterizadas por meio de imuno-histoquímica. Os resultados obtidos das imunomarcações foram comparados às graduações histopatológicas, bem como à mortalidade em função do tumor e ao tempo de sobrevida pós-cirúrgico. Observamos maior expressão de BAX em mastocitomas de grau III, bem como menor expressão de BCL2 em tumores de alto grau. A detecção imuno-histoquímica de BAX foi considerada um indicador prognóstico para sobrevida e mortalidade em função da doença, enquanto que as de APAF1 e BCL2 adicionaram valor prognóstico às graduações histopatológicas melhorando a previsão da sobrevida pós-cirurgia / Deregulation of apoptosis, especially in the mitochondrial pathway, plays a role in tumor progression, resistance to chemotherapy, and favor the formation of metastases by allowing the survival of tumor cells in the blood stream and other tissue microenvironments. In the present study, we evaluated 58 canine cutaneous mast cell tumors, from 50 dogs, which were submitted to excisional surgery alone. The tumors were graded according to the systems proposed by Patnaik, Ehler and MacEwen (1984) and Kiupel et al. (2011). The expression of the apoptosis-related proteins BCL2, BAX, APAF1, caspase 9 and caspase 3 was characterized by immunohistochemistry. Immunohistochemical results were compared with the histopathological grades, mortality due to the tumor and post-surgical survival time. We observed increased expression of BAX in grade III mast cell tumors and lower expression of BCL2 in high-grade tumors. Immunohistochemical detection of BAX was considered an independent indicator of prognosis for survival and mortality due to the disease, whereas APAF1 and BCL2 added prognostic value to the histopathological grading systems improving the prediction of survival post surgery

Le PCK3145 est un peptide de 15 acides aminés inhibant la sécrétion de MMP-9 et démontrant une activité anti-tumorale contre le cancer de la prostate. Comme les cancers hématologiques sécrètent MMP-9, nous avons donc évalué l’effet du PCK3145 sur ces cancers. Nous avons démontré que les lignées humaines de lymphome non- Hodgkinien (LNH) SR et de myélome multiple RPMI-8226 ainsi que la lignée murine de mastocytome P815 ont une prolifération réduite suite à une exposition au PCK3145. Ce peptide diminue également la clonogénicité de ces cellules. In vivo, le PCK3145 diminue significativement la croissance des tumeurs sous-cutanées P815 comparativement au PBS (p<0.001) et aux peptides contrôles (« scrambled peptide » (p<0.05) et PCK5266 (p<0.01)). De plus, le traitement au PCK3145 diminue le nombre de métastases au niveau du foie par rapports aux contrôles (p<0.05). Les niveaux de MMP-9 dans le sang des souris traitées au PCK3145 sont similaires à ceux dans le sang des souris sans tumeur. Par contre, chez les souris recevant le PBS ou le « scrambled peptide », les niveaux de MMP-9 étaient significativement plus élevés que dans les souris sans tumeur et les souris traitées au PCK3145 (p<0.05). De surcroît, dans un modèle de xénogreffe, le PCK3145 diminue significativement la croissance des lymphomes SR par rapport au PBS (p<0.01) et au « scrambled peptide » (p<0.001). Ces résultats indiquent que le PCK3145 possède une activité anti-tumorale et pourrait représenter un agent intéressant pour le traitement de plusieurs cancers hématologiques. / PCK3145 has been shown to exert anti-tumor activity against prostate cancer cells. In a Phase I clinical study, this peptide demonstrated low toxicity. To determine whether PCK3145 could exert cytotoxic activity against other marrow infiltrating cancers, we tested its activity against hematologic cancers. Interestingly, PCK3145 inhibited the proliferation of human NHL (SR) and myeloma (RPMI-8226) cell lines and murine mastocytoma (P815) cell line in vitro. Moreover, PCK3145 reduced the clonogenicity of these cell lines. To explore its activity in vivo, DBA/2 mice were injected with P815 cells. PCK3145 treatment significantly decreased P815 tumors growth in comparison to PBS (p<0.001), scrambled peptide (p<0.05) and PCK5266 (amino acids 52-66 of PSP-94) (p<0.01). Intraperitoneal PCK3145 treatment led to a decreased number of liver metastasis compared to PBS (p<0.05) and scrambled peptide (p<0.05). MMP-9 levels, measured by ELISA, in the peripheral blood of treated P815 bearing mice were similar to those obtained with healthy animals (12.83 1.890 (mean SD) ng/ml and 6.48 0.4070 ng/ml, respectively), while MMP-9 levels were elevated in mice treated with PBS and scrambled peptide (35.12 8.559 ng/ml and 22.60 3.944 ng/ml, respectively; p<0.05). In NOD/SCID mice PCK3145 treatment resulted in significant inhibition of human NHL SR growth compared to treatment with PBS (p<0.001) and scrambled peptide (p<0.01). Consequently, treatment with PCK3145 can reduce tumor cell proliferation of murine and human hematologic cancers. In addition, PCK3145 has the potential to inhibit tumor cells dissemination by lowering MMP-9 secretion. Thus, PCK3145 represents a unique peptide demonstrating sequence-specific anti-tumor activity hematologic malignancies.

Le PCK3145 est un peptide de 15 acides aminés inhibant la sécrétion de MMP-9 et démontrant une activité anti-tumorale contre le cancer de la prostate. Comme les cancers hématologiques sécrètent MMP-9, nous avons donc évalué l’effet du PCK3145 sur ces cancers. Nous avons démontré que les lignées humaines de lymphome non- Hodgkinien (LNH) SR et de myélome multiple RPMI-8226 ainsi que la lignée murine de mastocytome P815 ont une prolifération réduite suite à une exposition au PCK3145. Ce peptide diminue également la clonogénicité de ces cellules. In vivo, le PCK3145 diminue significativement la croissance des tumeurs sous-cutanées P815 comparativement au PBS (p<0.001) et aux peptides contrôles (« scrambled peptide » (p<0.05) et PCK5266 (p<0.01)). De plus, le traitement au PCK3145 diminue le nombre de métastases au niveau du foie par rapports aux contrôles (p<0.05). Les niveaux de MMP-9 dans le sang des souris traitées au PCK3145 sont similaires à ceux dans le sang des souris sans tumeur. Par contre, chez les souris recevant le PBS ou le « scrambled peptide », les niveaux de MMP-9 étaient significativement plus élevés que dans les souris sans tumeur et les souris traitées au PCK3145 (p<0.05). De surcroît, dans un modèle de xénogreffe, le PCK3145 diminue significativement la croissance des lymphomes SR par rapport au PBS (p<0.01) et au « scrambled peptide » (p<0.001). Ces résultats indiquent que le PCK3145 possède une activité anti-tumorale et pourrait représenter un agent intéressant pour le traitement de plusieurs cancers hématologiques. / PCK3145 has been shown to exert anti-tumor activity against prostate cancer cells. In a Phase I clinical study, this peptide demonstrated low toxicity. To determine whether PCK3145 could exert cytotoxic activity against other marrow infiltrating cancers, we tested its activity against hematologic cancers. Interestingly, PCK3145 inhibited the proliferation of human NHL (SR) and myeloma (RPMI-8226) cell lines and murine mastocytoma (P815) cell line in vitro. Moreover, PCK3145 reduced the clonogenicity of these cell lines. To explore its activity in vivo, DBA/2 mice were injected with P815 cells. PCK3145 treatment significantly decreased P815 tumors growth in comparison to PBS (p<0.001), scrambled peptide (p<0.05) and PCK5266 (amino acids 52-66 of PSP-94) (p<0.01). Intraperitoneal PCK3145 treatment led to a decreased number of liver metastasis compared to PBS (p<0.05) and scrambled peptide (p<0.05). MMP-9 levels, measured by ELISA, in the peripheral blood of treated P815 bearing mice were similar to those obtained with healthy animals (12.83 1.890 (mean SD) ng/ml and 6.48 0.4070 ng/ml, respectively), while MMP-9 levels were elevated in mice treated with PBS and scrambled peptide (35.12 8.559 ng/ml and 22.60 3.944 ng/ml, respectively; p<0.05). In NOD/SCID mice PCK3145 treatment resulted in significant inhibition of human NHL SR growth compared to treatment with PBS (p<0.001) and scrambled peptide (p<0.01). Consequently, treatment with PCK3145 can reduce tumor cell proliferation of murine and human hematologic cancers. In addition, PCK3145 has the potential to inhibit tumor cells dissemination by lowering MMP-9 secretion. Thus, PCK3145 represents a unique peptide demonstrating sequence-specific anti-tumor activity hematologic malignancies.

The failure of the immune system to provide efficient protection against tumour cells has been considered as a major issue in immunology. It is now well established that inadequate function of the host immune system is one of the main mechanisms by which tumours escape from immune control contributing to the limited success of cancer immunotherapy. Several cell populations have been described which display immunosuppressive properties and may impede tumor-specific immunity. Among them, GR1+CD11b+ immature myeloid suppressor cells and CD4+CD25+ regulatory T cells seem to play an important role. These cells accumulate in the spleens of tumour bearing mice and patients with cancer and contribute to immunosuppression by inhibiting the function of CD8+ T cells and/or by promoting tumour angiogenesis.<p><p>The aim of our work was to define the mechanisms by which a single dose of cyclophosphamide (CTX), a chemical agent commonly used in chemotherapy treatment, induces the rejection of established P815 mastocytoma. <p><p>Our data show that CTX treatment leads to the selective loss of GR1medCD11b+ splenic myeloid cell producing TGF-â, a cytokine which is known to suppress antitumoral response. Furthermore, injection of CTX causes a decrease in the number of naturally occurring regulatory T cells (CD4+CD25+Foxp3+) in the spleen and the tumor. Finally, CTX treatment induces the differentiation of GR1highCD11b+ splenic myeloid cells into mature GR1highCD11b+CD11c+ (possibly dendritic cells?) which express high levels of CD11c, MHC class II and CD86 molecules. Of note, these cells are mainly detected in tumour necrosis areas. <p><p>Collectively, these results suggest that CTX prevents suppressive mechanisms and induces a population of CD11c+ myeloid cells which may present tumor antigens and activate T lymphocytes, an hypothesis in line with the requirement for CD4+ cells in CTX-induced long term resistance. <p> / Doctorat en Sciences / info:eu-repo/semantics/nonPublished